Primary prevention group |
Patients more likely to discontinue and less likely to restart |
Women v men |
+6% |
−8% |
Age from 25 to 50 years v 60 years |
+111 to +16% |
−23% to 0% |
Age from 75 to 84 years v 60 years |
+4% to +29% |
−16% to −32% |
Body mass index from 15 to 23 v 25 |
+44% to +3% |
−12% to −1% |
Liver disease |
+17% |
— |
Cancer |
— |
−3% |
Dementia (long term statin use) |
+14% |
−20% |
Aspirin use |
+2% |
−8% |
Each other non-cardiovascular treatment |
+2% |
— |
Patients more likely to discontinue and more likely to restart |
Ethnic minority groups v white |
+25% to +89% |
+21% to +46% |
Current smoking, from light to heavy v non-smoking |
+7% to +16% |
+5% to +9% |
Chronic obstructive pulmonary disease |
+4% |
+6% |
Type 1 diabetes |
+18% |
+15% |
Patients less likely to discontinue or more likely to restart |
Ex-smoking v non-smoking |
−3% |
— |
Atrial fibrillation |
−4% |
— |
Hypertension |
−20% |
+8% |
Heart failure |
−8% |
— |
Type 2 diabetes |
−20% |
+35% |
Family history of heart disease |
— |
+4% |
Familial hypercholesterolaemia |
−14% |
+23% |
Anticoagulant use |
−12% |
−6% |
Secondary prevention group |
Patients more likely to discontinue and less likely to restart |
Women v men |
+14% |
−7% |
Age from 75 to 84 years v 60 years |
+10% to +35% |
−14% to −26% |
Body mass index from 15 to 23 v 25 |
+55% to +3% |
— |
Liver disease |
+22% |
— |
Chronic obstructive pulmonary disease |
+22% |
— |
Cancer |
+5% |
−4% |
Atrial fibrillation |
+5% |
−6% |
Type 1 diabetes |
+17% |
— |
Dementia (long term use) |
+22% |
— |
Familial hypercholesterolaemia |
+74% |
— |
Each other non-cardiovascular treatment |
+3% |
— |
Patients more likely to discontinue and more likely to restart |
Age from 25 to 50 v 60 years |
+166% to +11% |
+10% to +5% |
Ethnic minority groups v white |
+23% to +80% |
+35% to +58% |
Current smoking, from light to heavy v non-smoking |
+14% to +27% |
+4% to +11% |
Patients less likely to discontinue or more likely to restart |
Ex-smoking v non-smoking |
−4% |
+4% |
Hypertension |
−6% |
— |
Type 2 diabetes |
— |
+6% |
Aspirin use |
−17% |
+5% |
Anticoagulant use |
−11% |
— |